Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 22.25% is in line with its 5-year average of 20.86%, around the middle of its 5-year range (17.13%–24.76%).
1.13% above its 12-month average of 22.00%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 21.71%.
EBITDA MARGIN
22.25%
EBITDA MARGIN AVG TTM
22.00%
EBITDA MARGIN AVG 3Y
21.60%
EBITDA MARGIN AVG 5Y
20.86%
EBITDA MARGIN AVG 10Y
21.14%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.13%
CURRENT VS 3Y AVG
+3.02%
CURRENT VS 5Y AVG
+6.67%
CURRENT VS 10Y AVG
+5.23%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Medpace Holdings, Inc.
Market Cap
$17.32B
EBITDA Margin
22.25%
TTM Avg
22.00%
3Y Avg
21.60%
5Y Avg
20.86%
Market Cap
$19.04B
EBITDA Margin
29.84%
TTM Avg
29.78%
3Y Avg
28.27%
5Y Avg
25.91%
Market Cap
$15.60B
EBITDA Margin
32.07%
TTM Avg
25.68%
3Y Avg
26.69%
5Y Avg
27.49%
Market Cap
$21.24B
EBITDA Margin
50.36%
TTM Avg
50.37%
3Y Avg
51.80%
5Y Avg
47.75%
Market Cap
$13.14B
EBITDA Margin
22.69%
TTM Avg
18.62%
3Y Avg
20.95%
5Y Avg
21.80%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $17.32B | 22.25% | 22.00% | 21.60% | 20.86% |
| Revvity, Inc. (RVTY)vs › | $15.64B | 23.07% | 26.75% | 30.05% | 32.80% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $19.04B | 29.84% | 29.78% | 28.27% | 25.91% |
| Solventum Corporation (SOLV)vs › | $15.60B | 32.07% | 25.68% | 26.69% | 27.49% |
| Viatris Inc. (VTRS)vs › | $19.39B | 0.95% | 10.32% | 17.98% | 18.96% |
| Exelixis, Inc. (EXEL)vs › | $14.30B | 38.84% | 34.03% | 26.26% | 22.70% |
| STERIS plc (STE)vs › | $20.49B | 26.76% | 25.68% | 26.35% | 25.75% |
| United Therapeutics Corporation (UTHR)vs › | $21.24B | 50.36% | 50.37% | 51.80% | 47.75% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.14B | 22.69% | 18.62% | 20.95% | 21.80% |
| Penumbra, Inc. (PEN)vs › | $12.54B | 14.73% | 11.96% | 9.26% | 5.60% |
Gross Margin
28.8%
EBITDA Margin
22.3%
Operating Margin
21.0%
Net Margin
17.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 21.71% |
| 2026-03-31 | 21.00% |
| 2025-12-31 | 22.64% |
| 2025-09-30 | 22.56% |
| 2025-06-30 | 22.10% |
| 2025-03-31 | 21.56% |
| 2024-12-31 | 24.76% |
| 2024-09-30 | 22.46% |
| 2024-06-30 | 21.28% |
| 2024-03-31 | 21.73% |
| 2023-12-31 | 18.92% |
| 2023-09-30 | 18.64% |
| 2023-06-30 | 18.42% |
| 2023-03-31 | 21.23% |
| 2022-12-31 | 20.89% |
| 2022-09-30 | 21.79% |
| 2022-06-30 | 18.73% |
| 2022-03-31 | 20.94% |
| 2021-12-31 | 19.55% |
| 2021-09-30 | 19.98% |
| 2021-06-30 | 17.13% |
| 2021-03-31 | 20.27% |
| 2020-12-31 | 23.29% |
| 2020-09-30 | 22.30% |
| 2020-06-30 | 16.97% |
| 2020-03-31 | 17.31% |
| 2019-12-31 | 18.03% |
| 2019-09-30 | 16.21% |
| 2019-06-30 | 18.79% |
| 2019-03-31 | 16.80% |
| 2018-12-31 | 21.04% |
| 2018-09-30 | 20.45% |
| 2018-06-30 | 19.37% |
| 2018-03-31 | 18.29% |
| 2017-12-31 | 23.99% |
| 2017-09-30 | 26.15% |
| 2017-06-30 | 26.21% |
| 2017-03-31 | 25.82% |
| 2016-12-31 | 25.42% |
| 2016-09-30 | 25.23% |
| 2016-06-30 | 26.97% |
| 2016-03-31 | 27.42% |
| 2015-12-31 | 14.47% |
| 2015-09-30 | 26.68% |
| 2015-06-30 | 30.10% |
| 2015-03-31 | 30.30% |
| 2014-03-31 | 11.38% |
